The NETest® – can it replace Chromogranin A and more?

• Facebook
• X
• Bluesky
• Pinterest
• Threads
• WhatsApp
• Mail

See Summary below for a quick update

Update 8th Dec 2025. 

New York State Department of Health Grants Approval of Wren Laboratories’ NETest® 2.0 for Clinical Use

Clinically Validated Performance

In validation across 3,042 NET patients and 1,084 controls/other cancers, NETest 2.0 demonstrated:

• Sensitivity: 93%
• Specificity: 85%
• Positive predictive value: 95%
• Negative predictive value: 82%
• Overall accuracy: 91%

These results support broad clinical utility, including:

• Accurate detection across all NET grades and stages
•  Identification of minimal residual disease, recurrence, and progression
• Monitoring and prediction of therapeutic response, including 177Lu-PRRT
• Prognostic value for progression-free and overall survival
• Detection of neuroendocrine differentiation in select epithelial tumors

Click here to read

Please note this approval does not mean NETest 2.0 is now used in routine clinical practice. It simply means the test is legally permitted to be performed on patients in New York State. It does not change guideline status, reimbursement, or clinical adoption.

Update 17th Feb 2025. 

NETest® 2.0—A decade of innovation in neuroendocrine tumor diagnostics

Citation here
Kidd, Mark & Drozdov, I & Chirindel, A & Nicolas, G & Imagawa, D & Gulati, A & Tsuchikawa, T & Prasad, V & Halim, A & Strosberg, J. (2025). NETest® 2.0-A decade of innovation in neuroendocrine tumor diagnostics. Journal of neuroendocrinology. e70002. 10.1111/jne.70002.

Click here to read

Update 20th Aug 2023.

NEW YORK – Wren Laboratories announced Thursday that it finalized a distribution agreement with Kindstar Globalgene Technology to distribute Wren’s blood-based neuroendocrine tumor NETest throughout China. Click the link below.

https://wrenlaboratories.com/netest-expanded-to-china/

Tumour Markers General

For some years the gold standard tumour marker for Neuroendocrine Neoplasms (NENs) has been and remains today, Chromogranin A (and for certain scenarios Chromogranin B and C can provide some additional clues).  Pancreastatin, which is actually a molecule of Chromogranin A, is another marker touted but appears to be limited to USA. Its main advantage is the ability to better handle the effects of Proton Pump Inhibitor (PPI) use which is prevalent in the general population.  As we move to a new era of molecular/genetic tumour markers, there’s a danger that NENs will be left behind, stuck with diagnostic tools not capable of meeting new demands.

I see a lot of public criticism of Chromogranin A, but it’s mainly directed at the problem of being skewed by the use of PPIs and other conditions such as renal disease. To quote one internationally known US NET Specialist “The problem is so many people take proton pump inhibitors”.

As for my own experience of Chromogranin A, it was elevated at diagnosis, remained elevated after primary surgery and then only subsided after liver surgery.  It had a minor spike in 2012 resulting from growth of some known lymph node metastases and then returned to normal after a lymphadenectomy.  It has been in range since and no major spikes in tumour growth according to my routine surveillance scans. As a layman, this would indicate Chromogranin A has been a good indication of my tumour bulk at the times of testing.  But I’ve never had any requirement to take PPIs or have any renal issues of note, so perhaps for someone like myself, Chromogranin A is an adequate marker and I guess a trend of increasing scores downstream might indicate signs worth checking further.  However, if there’s something out there which is better, then I’m interested.

What is NETest?

The Neuroendocrine testing capability from Wren Laboratories is not new.  They’ve been around for some time and I remember the “Wren Test” being talked about a few years ago.  Back then it was receiving mixed reviews from patients and physicians.  Looking at where they are in 2020, it looks like they’ve been busy and have new data backed by many known NET specialists from Europe and USA.

According to their website, the NETest is a non-invasive procedure using a blood sample to inform your doctor. Use of the NETest provides additional information about disease status, complimentary to imaging and may decrease radiation exposure by reducing the need for repetitive imaging. NETesting provides an assessment of treatment responses in neuroendocrine tumor patients in conjunction with standard clinical assessment. Interpretation of the test will facilitate identification of active disease and enable a determination of the efficacy of the current treatment modality. NETesting is as easy as having your blood drawn, and provides clinicians and patients with the information to better manage treatment.

What’s different from Chromogranin A?

Both are blood draws but note the use of the word ‘molecular’ in the NETest specification which is significant.  Chromogranin A and Pancreastatin are single value measurements but the NETest digs deeper proving richer information. NETest represents a molecular measurement of a variety of different gene transcripts (molecular information) in the blood which indicate the biological nature of the tumor and the extent of its progression.  Also, NETest provides additional information to patients and physicians over and above a test result.  It can also allow physicians to adjust therapy appropriately to better manage the disease and provides the patient with added information to understand, in real-time, the status of their disease. Both clinicians and patients are therefore far better informed and supported. The patient has a more precise understanding of their condition and the clinician has an added tool to gauge the effectiveness of the therapy that is being administered.  This is done via the NETest algorithm which not only accurately diagnoses GEP–NENs but also provides a measure of their biological activity.

What is this additional information and is the NETest a better marker for NENs? 

This is quite technical but I’ve attached abstract statements here and the ability for you to dig deeper if you so wish.  These are all coming from documents authored by well known NET specialists and should therefore hold weight.  I would like to construct a frequently asked question over time to replace this complexity. In the meantime, some evidence is below.

This one published in late 2019/early 2020 is useful. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood K. Öberg, A. Califano , J. R. Strosberg , S. Ma , U. Pape , L. Bodei, G. Kaltsas , C. Toumpanakis , J. R. Goldenring , A. Frilling & S. Paulson

The document concluded “The NETest is an accurate biomarker suitable for clinical use in NET disease management. The metaanalysis supports the utility of the NETest as an IVD to establish a diagnosis and monitor therapeutic efficacy. The use of this as a biomarker provides information relevant to NET management consistent with observations regarding utility of liquid biopsies in other oncological disciplines.” Note: IVD means in vitro diagnostic, i.e. in a clinical trial setting

A technical document entitled In The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood by Irvin M. Modlin*, Ignat Drozdov, Mark Kidd, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, United States of America, I noted the conclusion using computational and machine learning approaches, including analysis and integration of tumor tissue and circulating peripheral blood transcripts, we identified a panel of 51 marker genes selectively associated with GEP-NENs. The test can differentiate between GEP-NENs and controls and has a high PPV and NPV (.90%). It is more accurate than the currently used clinical standard Chromogranin A (CgA) assay, which identifies a single peptide related only to tumor secretion. The PCR-based signature measures multiple transcripts which reflect the diverse biological profile of a proliferating NEN and may, with further examination in appropriate studies, be tested as a measure of tumor responsiveness and, potentially, as a prognostic.

Above I noted that it could allow therapy adjustments to the richer information is provides and an example of this related to PRRT can be found in a technical paper from Bodei, L., Kidd, M.S., Singh, A. et al. PRRT genomic signature in blood for prediction of ¹⁷⁷Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging 45, 1155–1169 (2018).

In one small study, NETest was described as a liquid biopsy which was diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.  The paper from Malczewska, A.; Witkowska, M.; Makulik, K.; Bocian, A.; Walter, A.; Pilch-Kowalczyk, J.; Zajęcki, W.; Bodei, L.; Oberg, K.E.; Kos-Kudła, B. was published in Endocrine Connections 2019   Only the abstract is shown as it’s a paid article but the abstract is sufficient for most patients to understand.

This document published by the European Journal of Cardio-Thoracic Surgery, Pier Luigi Filosso, Kjell Öberg, Anna Malczewska, Anna Lewczuk, Matteo Roffinella, Harry Aslanian, Lisa Bodei looked at efficacy in Lung Neuroendocrine Neoplasms and concluded that this gene-based liquid biopsy is an effective and accurate method for diagnosing lung tumours with neuroendocrine gene expression. CgA has no value. An NETest score >40 provides an accurate (94–97%) rule-in for the diagnosis of NEN and a rule-out for benign and other neoplastic diseases. Because neuroendocrine gene expression is associated with a poor prognosis, NETest levels may have utility both in the diagnosis of and the treatment stratification for lung neoplasia.

This document published by BMC Gastroenterology concluded NETest is diagnostic for gastric NETs. Elevated levels identify both microscopic and macroscopic residual disease. In histology/image-negative disease, elevated NETest may reflect early evidence of increased neuroendocrine gene expression of hypergastrinemia-induced neoplastic transformation of enterochromaffin-like (ECL) cells to tumor status. A sensitive liquid biopsy has utility in the management and surveillance of gastric NET disease.  NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual disease: A. Malczewska, A. Procner, A. Walter, K. Kusnierz, W. Zajecki, H. Aslanian & B. Kos-Kudla  BMC Gastroenterology Volume 20, Article number: 235 (2020) 

Another and more recent article confirmed the superiority of NETest over Chromogranin A published in Neuroendocrinology, Blood Molecular Genomic Analysis Predicts the Disease Course of GEP NET Patients: A Validation Study of the Predictive Value of the NETest® Mark J C van Treijen, Dennis van der Zee, Birthe C Heeres, Femke C R Staal, Menno R Vriens, Lisette J Saveur, Wieke H M Verbeek, Catharina M Korse, Monique Maas, Gerlof D Valk, Margot Tesselaar PMID: 32492680 DOI: 10.1159/000509091.

You can also read the technical documentation on Wren Laboratories here.  I think the short video from Dr Modlin is probably useful for patients – click below to watch. Irvin Modlin is a well known NET specialist and of the original group of renowned NET specialists

Summary

I think I have many questions still not answered, or answered sufficiently for a full understanding at the patient level, so I will attempt more research, perhaps with Wren Laboratories to flesh out an FAQ on NETest for publishing as part of this article.  I’ll end by saying this to patients (at the international level), introducing a new marker test doesn’t happen overnight, there are many factors involved including approvals (nationally and locally) and this involves cost, insurance approvals (where applicable), availability of the test and probably many other factors.  That said, in the USA, it looks like you or your doctor can order a test (see their website above) but I’ve no idea how if this is a private purchase or insurance covered.

Summary

The WREN NETest (including NETest 2.0) is still not used in routine clinical practice in 2026. It remains a CLIA‑certified laboratory-developed test (LDT) available commercially from Wren Laboratories, but it has not been adopted into major international NET guidelines (ENETS, NANETS, ESMO, NCCN) for standard care.

Current Status (2026)

✔ Available commercially

• The test is fully operational and marketed by Wren Laboratories in the US as a blood-based 51‑gene expression assay for diagnosis, prognosis, and treatment monitoring.

• NETest 2.0 (2025 update) shows improved performance metrics (AUROC ~0.9 for diagnosis; strong sensitivity/specificity).

Not adopted into routine clinical guidelines

Across all major NET societies:

• ENETS – does not recommend NETest for routine diagnosis, monitoring, or treatment decisions.

• NANETS – same position.

• ESMO – continues to rely on imaging, pathology, and selective biomarkers (CgA, 5‑HIAA) rather than multigene assays.

• NCCN – does not include NETest in standard work‑up or surveillance pathways.

Not widely reimbursed

• Outside the US, it is rarely ordered because it is not reimbursed, not CE‑marked as an IVD, and not integrated into national health systems (including the NHS).

Why It Hasn’t Entered Routine Use

1. Evidence base is still considered insufficiently independent

Most validation studies are:

• authored or co-authored by Wren Laboratories scientists, or

• conducted in highly selected cohorts.

Guideline committees prefer:

• multi‑centre, prospective, independently funded trials

• clear demonstration of clinical utility (i.e., does it change outcomes?)

2. Lack of demonstrated impact on treatment decisions

Even if the test correlates with disease activity, guidelines require proof that:

• using the test improves survival,

• or reduces unnecessary imaging,

• or optimises therapy sequencing.

That evidence is not yet established.

3. Variability concerns (historically)

Earlier versions (NETest 1.0) had:

• fluctuating serial scores,

• false positives in non‑NET cancers and lung disease,

• issues with EDTA vs PaxGene tube collection.

NETest 2.0 addresses many of these, but guideline bodies move slowly.

4. Regulatory status

• It is a US LDT, not an FDA‑approved diagnostic.

• In Europe, it is not an IVDR‑approved assay, so cannot be integrated into routine hospital labs.

What Clinicians Actually Do in Practice (2026)

Most NET centres still rely on:

• Imaging (CT/MRI, ^68Ga/64Cu SSTR PET, FDG PET for high grade)

• Pathology (Ki‑67, grade, differentiation)

• Selective biomarkers (CgA, 5‑HIAA, pancreastatin in some US centres)

• Clinical course + symptom tracking

NETest may be used:

• in research settings,

• by individual clinicians who are early adopters,

• or by patients who self-pay in the US.

But it is not part of standard-of-care pathways.

Bottom Line

Despite strong analytical performance and a decade of development, the WREN NETest (including NETest 2.0) has not crossed the threshold into routine clinical use. It remains a promising but non‑standard biomarker awaiting broader independent validation and guideline endorsement.

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted.  Please check any references attached.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Click here and answer all questions to join my private Facebook group

Facebook


Twitter


WordPress


Instagram

Thanks for reading.

Ronny

Check out my Glossary of Terms – click here

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

Neuroendocrine Tumours (NET) – Vitamin B12 (Cobalamin)February 27, 2026Ronny AllanDiet and Nutrition

Understanding your Somatostatin Receptor (SSTR) PET/CT Scan ResultsJuly 9, 2024Ronny AllanPatient Advocacy

A Spotlight on NET Syndromes – Carcinoid SyndromeDecember 3, 2023Ronny AllanA spotlight on NENs

Cancer: Words are important but so is contextMarch 11, 2026Ronny AllanInspiration

Don't believe the hype – Neuroendocrine Cancer Myths debunkedFebruary 16, 2025Ronny AllanAwareness

Jimmy Buffett 1946-2023 – Neuroendocrine Carcinoma (Merkel Cell Carcinoma)September 3, 2023Ronny AllanAwareness

Evidence of disease but stableOctober 10, 2022Ronny AllanInspiration

All you need to know about Peptide Receptor Radionuclide Therapy (PRRT)May 8, 2017Ronny AllanClinical Trials and Research

CAR-T clinical trials for Neuroendocrine Cancer (plus bonus section on CAR-NK)August 31, 2024Ronny AllanClinical Trials and Research

The 5 E's (of Carcinoid Syndrome)August 27, 2024Ronny AllanAwareness